|
1. |
Spreading the Wealth: Antigen Discovery in Adult Tumors Can Help Hone the Search for Pediatric Tumor Antigens |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 281-282
Crystal Mackall,
Preview
|
|
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
2. |
Preventing Epstein-Barr Virus Lymphoproliferative Disease After Bone Marrow Transplantation |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 283-284
Helen Heslop,
Preview
|
|
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
3. |
The Effects of Limb Perfusion With Tumor Necrosis Factor on Circulating Levels of Proinflammatory Cytokines |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 285-286
H. Alexander,
Preview
|
|
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
4. |
Guidelines for the Safe Administration of High-Dose Interleukin-2 |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 287-293
Douglas Schwartzentruber,
Preview
|
PDF (63KB)
|
|
摘要:
High-dose interleukin-2 (IL-2) results in objective clinical regression of metastatic cancer in 15% to 17% of patients with melanoma and renal cell carcinoma. Durable complete regression of all metastases is seen in 6% to 8% of patients. Based on these findings, the U.S. Food and Drug Administration has approved the use of high-dose IL-2 for the treatment of patients with metastatic melanoma and renal cell carcinoma. Interleukin-2 administration is associated with many different side effects, and after many years of use, clinicians have learned how to safely administer high-dose IL-2. This article details practical guidelines for the safe administration of high-dose IL-2.
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
5. |
Dendritic Cell–Dead Cell Interactions: Implications and Relevance for Immunotherapy |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 294-304
Jean-Francois Fonteneau,
Marie Larsson,
Nina Bhardwaj,
Preview
|
PDF (2085KB)
|
|
摘要:
Dendritic cells are a system of antigen-presenting cells with an essential role in the initiation and development of immune responses against infections or tumors. Their unique capacity to stimulate T cells is being adapted for use in immunotherapy. In this review, we focus on their ability to interact with dead cells and, notably, to present exogenous antigens acquired from them to CD8+T cells. We also discuss the role of this unique antigen presentation pathway for immunotherapeutic development.
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
6. |
Major Histocompatibility Complex–Restricted Lysis of Neuroblastoma Cells by Autologous Cytotoxic T Lymphocytes |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 305-311
Asis Sarkar,
Susan Burlingame,
Ying Zang,
Vicky Dulai,
M. Hicks,
Douglas Strother,
Jed Nuchtern,
Preview
|
PDF (266KB)
|
|
摘要:
Vigorous host immune reactivity to neuroblastoma may correlate with better prognosis, but identification of human cytotoxic T-lymphocyte (CTL) responses has been relatively unsuccessful. We generated neuroblastoma-reactive CTL lines from two human leukocyte antigen (HLA) A2+neuroblastoma patients by stimulation of peripheral blood lymphocytes (PBLs) with irradiated autologous tumor cells pretreated with interferon-&ggr; in the presence of low concentrations of interleukin-2 (5 U/mL). These lines lyse autologous tumor cells but do not kill HLA mismatched allogeneic tumor cells, Epstein-Barr virus–transformed autologous B cells, or standard natural killer cell targets. Cytotoxic T lymphocytes generated from one patient recognize tumor cells from several HLA-A2 matched children, although the other patient's CTLs do not kill tumor cells from other HLA-A2+individuals. Pretreatment of CTLs or target cells with appropriate standard monoclonal antibodies demonstrates that these CTLs are major histocompatibility complex class I (HLA-A2) restricted and that the effector cell population is CD8+. Our findings suggest that these tumor cells express at least one common HLA-A2 restricted antigen and at least one unique private epitope. Autologous tumor-specific CTLs can be readily generated from patients' PBLs and maintained in long-term culture using standard techniques.
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
7. |
In Vitro Generation of Epstein-Barr Virus–Specific Cytotoxic T Cells in Patients Receiving Haplo-Identical Allogeneic Stem Cell Transplantation |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 312-322
Philip Musk,
Susann Szmania,
Amanda Galloway,
Ken Johnson,
Alycia Scott,
Stephen Guttman,
Kerry Bridges,
Mary Bruorton,
Joel Gatlin,
J. Garcia,
Larry Lamb,
K. Chiang,
Trent Spencer,
Jean Henslee-Downey,
Frits van Rhee,
Preview
|
PDF (475KB)
|
|
摘要:
Use of a partially mismatched related donor (PMRD) is an option for patients who require allogeneic transplantation but do not have a matched sibling or unrelated donor. Epstein-Barr virus (EBV)–induced lymphoma is a major cause of mortality after PMRD transplantation. In this study, we present a clinical grade culture system for donor-derived EBV-specific cytotoxic T cells (CTLs) that do not recognize haplo-identical recipient cells. The EBV-specific CTLs were tested for cytolytic specificity and other functional properties, including ability to transgress into tissues, propensity for apoptosis, degree of clonality, stability of dominant T-cell clones, and Tc and Th phenotypes. The EBV-specific CTLs were routinely expanded to greater than 80 × 106over a period of 5 weeks, which is sufficient for clinical application. A CD8+phenotype predominated, and the CTLs were highly specific for donor lymphoblastoid cell lines (LCLs) without killing of recipient targets or K562. V&bgr; spectratyping showed an oligoclonal population that was stable on prolonged culture. The EBV-specific CTLs were activated (D-related human leukocyte antigen [HLA-DR+], L-selectin+/−) and of memory phenotype (CD45RO+). Expression of the integrin VLA-4 suggested that these CTLs could adhere to endothelium and migrate into tissues. The Bcl-2 message was upregulated, which may protect the CTLs from the apoptosis. The first demonstration of overexpression of bcl-2 in human memory CTLs. In addition, we show that lymphoblastoid cell lines used to generate CTLs are readily genetically modified with recombinant lentivirus, indicating that genetically engineered antigen presentation is feasible.
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
8. |
Melanoma-Reactive CD8+T Cells Recognize a Novel Tumor Antigen Expressed in a Wide Variety of Tumor Types |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 323-333
Mamoru Harada,
Yong Li,
Mona El-Gamil,
Galen Ohnmacht,
Steven Rosenberg,
Paul Robbins,
Preview
|
PDF (1432KB)
|
|
摘要:
An autologous melanoma cell line selected for loss of expression of the immunodominant MART-1 and gp100 antigens was initially used to carry out a mixed lymphocyte tumor culture (MLTC) in a patient who expressed the human leukocyte antigen (HLA)-A1 and HLA-A2 class I major histocompatibility complex alleles. Ten clones identified from this MLTC seemed to recognize melanoma in an HLA-A1–restricted manner but failed to recognize a panel of previously described melanoma antigens. The screening of an autologous melanoma cDNA library with one HLA-A1–restricted melanoma-reactive T-cell clone resulted in the isolation of a cDNA clone called AIM-2 (antigen isolated from immunoselected melanoma-2). The AIM-2 transcript seemed to have retained an intronic sequence based on its alignment with genomic sequences as well as expressed sequence tags. This transcript was not readily detected after Northern blot analysis of melanoma mRNA, indicating that only low levels of this product may be expressed in tumor cells. Quantitative reverse transcriptase–polymerase chain reaction analysis, however, demonstrated a correlation between T-cell recognition and expression in HLA-A1–expressing tumor cell lines. A peptide that was encoded within a short open reading frame of 23 amino acids and conformed to the HLA-A1 binding motif RSDSGQQARY was found to represent the T-cell epitope. The AIM-2–reactive T-cell clone recognized a number of neuroectodermal tumors as well as breast, ovarian, and colon carcinomas that expressed HLA-A1, indicating that this represents a widely expressed tumor antigen. Thus, AIM-2 may represent a potential target for the development of vaccines in patients bearing tumors of a variety of histologies.
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
9. |
Monoclonal Antibody Identifies a Distinctive Epitope Expressed by Human Multiple Myeloma Cells |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 334-344
Pamela Krueger,
Christina Nitz,
Jason Moore,
Randi Foster,
Oren Gelber,
Cohava Gelber,
Preview
|
PDF (2724KB)
|
|
摘要:
Employing a technology called differential immunization for antigen and antibody discovery (DIAAD), we aimed to generate monoclonal antibodies (mAbs) specific to human multiple myeloma (MM) cells. The fundamental principles of DIAAD rely on the induction of high zone tolerance to the “wild type” (normal) antigen, followed by immunization with the modified (diseased) antigen. Because chronic myelogenic leukemia (CML) cells are derived from a lineage closely related to MM, we immunized mice by contrasting a pool of MM cells with CML cells. Monoclonal antibody VAC69 reacted exclusively with MM cells, identifying a membrane molecule composed of a single-chain glycoprotein with a molecular weight of 78–120 kd. This antigen exhibited narrow tissue specificity and was not found on human cancers such as prostate, breast, or cervical carcinoma; leukemia; or lymphoma, nor was it seen on normal human peripheral lymphocytes or on Epstein-Barr virus–transformed B-cell lines. By immunohistochemistry, mAb VAC69 showed no binding to antigens expressed on normal human ovary, breast, prostate, lung or colon tissue, nor did it bind to human breast or prostate cancer. Conversely, mAb VAC69 bound strongly to human MM, although showing only slight binding to histiocytes or inflamed cells in human lymph nodes and human tumors of the colon, lung, and ovary. Monoclonal antibody VAC69 also triggered cancer-specific cytotoxicity in vitro (in the presence of complement) as well as in vivo using a sever combined immunodeficiency model transplanted with human MM. Further studies showed the ability of mAb VAC69 to be specifically internalized by human MM cells, indicating its potential use for therapeutic intervention in MM by delivering drugs into cancer cells.
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
10. |
Adenovirus-Mediated MUC1 Gene Transduction into Human Blood-Derived Dendritic Cells |
|
Journal of Immunotherapy,
Volume 24,
Issue 4,
2001,
Page 345-353
Kouji Maruyama,
Yasuto Akiyama,
Noriko Nara-Ashizawa,
Takashi Hojo,
Jin-Yan Cheng,
Hiroyuki Mizuguchi,
Takao Hayakawa,
Ken Yamaguchi,
Preview
|
PDF (5862KB)
|
|
摘要:
MUC1 protein is widely expressed on various human cancer cells and has a specific highly glycosylated core structure with multiple tandem repeats, which may include an immunogenic peptide sequence. The potency of MUC1 protein to induce human histocompatibility leukocyte antigen–class I–restricted cytotoxic T-lymphocyte (CTL) induction remains to be fully clarified in human beings. In the current study, we made MUC1-expressing human dendritic cells (DCs) using recombinant adenovirus vector. Adenovirus vector plasmid containing human MUC1 cDNA, pAdHM4-MUC1 was constructed using in vitro ligation with a shuttle vector, pHMCMV5. Adenovirus vector expressing MUC1 was generated by the transfection ofPacI-digested recombinant vector plasmid into 293 cells. Human blood DCs were obtained from 7-day culture of monocytes with recombinant human (rh) granulocyte-macrophage (GM) colony-stimulating factor (CSF) and (rh)interleukin (IL)-4. Then, 1 × 106DCs were incubated with viral supernatant at a multiplicity of infection of 200 for 24 h in the presence of rhGM-CSF and rhIL-4. Flow cytometric analysis showed that 30% to 40% of the transduced DCs expressed MUC1 protein; by contrast, nontransduced or transduced DCs with mock virus expressed only small amounts of MUC1 protein. Adenovirus-mediated MUC1 gene transduction into DCs had no significant effect on DC surface marker expressions or functions such as mixed leukocyte reaction. Furthermore, MUC1-specific CD8+CTLs could be induced from healthy donor blood lymphocytes using MUC1-expressing DCs as stimulators. These results suggested that MUC1 gene-transduced DCs are a functional and potent tool for triggering a CTL response against MUC1+cancer cells.
ISSN:1524-9557
出版商:OVID
年代:2001
数据来源: OVID
|
|